Skip to main content

Advertisement

SpringerLink
Log in

Low-density lipoprotein apheresis as a treatment option for hyperlipidemia

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Data support the relevance of blood cholesterol levels, particularly high levels of low-density lipoprotein (LDL), in the pathogenesis and progression of atherosclerosis. A strong and continuous relationship between dyslipidemia and vascular morbidity and mortality has been established. The initial approach to treating dyslipidemia consists of lifestyle modifications followed by pharmacologic therapy, usually beginning with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Some patients with familial hypercholesterolemia (FH) fail to achieve their LDL goal despite aggressive pharmacologic therapy. In certain cases, LDL apheresis may be an effective therapeutic option. In the United States, LDL apheresis is approved for homozygous FH patients with an LDL cholesterol level ≥ 500 mg/dL. For patients with heterozygous FH, LDL apheresis may be offered if their LDL is ≥ 300 mg/dL, or ≥ 200 mg/dL with known coronary artery disease, despite maximum medical treatment. This review focuses on the principles and methods of LDL apheresis, its potential benefit in clinical care, and its current indications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.

  2. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.

    Article  Google Scholar 

  3. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340–2346.

    Article  PubMed  CAS  Google Scholar 

  4. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301–1307.

    Article  PubMed  CAS  Google Scholar 

  5. Gordon BR, Saal SD: Advances in LDL-apheresis for the treatment of severe hypercholesterolemia. Curr Opin Lipidol 1994, 5:69–73.

    Article  PubMed  CAS  Google Scholar 

  6. Vella A, Pineda AA, O’Brien T: Low density lipoprotein apheresis for the treatment of refractory hypercholesterolemia. Mayo Clin Proc 2001, 76:1039–1046.

    Article  PubMed  CAS  Google Scholar 

  7. Kavey RE, Allada V, Daniels SR, et al.: Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006, 114:2710–2738.

    Article  PubMed  Google Scholar 

  8. Richter WO, Jacob BG, Ritter MM, et al.: Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 1993, 42:888–894.

    Article  PubMed  CAS  Google Scholar 

  9. Thompson GR: Recommendation for the use of LDL apheresis. Atherosclerosis 2008, 198:247–255.

    Article  PubMed  CAS  Google Scholar 

  10. Apstein CS, Zilversmit DB, Lees RS, et al.: Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis 1978, 31:105–115.

    Article  PubMed  CAS  Google Scholar 

  11. Thompson GR, Lowenthal R, Myant NB: Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975, 1:1208–1211.

    Article  PubMed  CAS  Google Scholar 

  12. Thompsen J, Thompson PD: A systemic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006, 189:31–38.

    Article  PubMed  CAS  Google Scholar 

  13. Bosch T, Schmidt B, Blumenstein M, Gurland HJ: Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs 1993, 17:640–652.

    Article  PubMed  CAS  Google Scholar 

  14. Koga N: Efficacy and safety measures for low density lipoprotein apheresis treatment using dextran sulfate cellulose columns. Ther Apher 1999, 3:155–160.

    PubMed  CAS  Google Scholar 

  15. Yokoyama S, Hayashi R, Satani M, et al.: Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 1985, 5:613–622.

    PubMed  CAS  Google Scholar 

  16. Gordon BR, Stein E, Jones P, et al.: Indications for low-density lipoprotein apheresis. Am J Cardiol 1994, 74:1109–1112.

    Article  PubMed  CAS  Google Scholar 

  17. Ziajka P: Role of low-density lipoprotein apheresis. Am J Cardiol 2005, 96:67E–69E.

    Article  PubMed  Google Scholar 

  18. Seidel D, Armstrong VW, Schuff-Werner P: The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease I. HELP Study Group. Eur J Clin Invest 1991, 21:375–383.

    Article  PubMed  CAS  Google Scholar 

  19. Mabuchi H, Koizumi J, Shimizu M, et al.: Long term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998, 82:1489–1495.

    Article  PubMed  CAS  Google Scholar 

  20. Schuff-Werner P, Gohlke H, Bartmann U, et al.: The HELP-LDL-apheresis multicentre study, and angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease II. HELP Study Group. Eur J Clin Invest 1994, 24:724–732.

    Article  PubMed  CAS  Google Scholar 

  21. Waidner T, Franzen D, Voelker W, et al.: The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. Clin Investig 1994, 72:858–863.

    Article  PubMed  CAS  Google Scholar 

  22. Richter WO, Donner MG, Hofling B, et al.: Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 1998, 47:863–868.

    Article  PubMed  CAS  Google Scholar 

  23. Park JW, Merz M, Braun P: Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J Heart Lung Transplant 1997, 16:290–297.

    PubMed  CAS  Google Scholar 

  24. Hoffmann U, Derfler K, Haas M, et al.: Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography. Am J Cardiol 2003, 91:461–464.

    Article  PubMed  CAS  Google Scholar 

  25. Thompson GR, Maher VM, Matthews S, et al.: Familial Hypercholesterolemia Regression Study: a randomized trial of low-density-lipoprotein apheresis. Lancet 1995, 345:811–816.

    Article  PubMed  CAS  Google Scholar 

  26. Kroon AA, Aengevaeren WR, van der Wef T, et al.: LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996, 93:1826–1835.

    PubMed  CAS  Google Scholar 

  27. Nishimura S, Sekiguchi M, Kano T, et al.: Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999, 144:409–417.

    Article  PubMed  CAS  Google Scholar 

  28. Matsuzaki M, Hiramori K, Imaizumi T, et al.: Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 2002, 40:220–227.

    Article  PubMed  Google Scholar 

  29. Hennerici M, Kleophas W, Gries FA: Regression of carotid plaques during low density lipoprotein cholesterol elimination. Stroke 1991, 22:989–992.

    PubMed  CAS  Google Scholar 

  30. Koga N, Watanabe K, Kurashige Y, et al.: Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients. J Intern Med 1999, 246:35–43.

    Article  PubMed  CAS  Google Scholar 

  31. Kroon AA, van Asten WN, Stalenhoef AF: Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996, 125:945–954.

    PubMed  CAS  Google Scholar 

  32. Kinlay S, Egido J: Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol 2006, 98:2P–8P.

    Article  PubMed  CAS  Google Scholar 

  33. Kuo LT, Yang NI, Cherng WJ, et al.: Serum interleukin-6 levels, not genotype, correlate with coronary plaque complexity. Int Heart J 2008, 49:391–402.

    Article  PubMed  CAS  Google Scholar 

  34. Wang X, Chai H, Wang Z, et al.: Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2008, 295:H2399–H2408.

    Article  PubMed  CAS  Google Scholar 

  35. Thompson SG, Kienast J, Pyke SD, et al.: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995, 332:635–641.

    Article  PubMed  CAS  Google Scholar 

  36. Wang Y, Blessing F, Walli AK, et al.: Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins—reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004, 175:145–150.

    Article  PubMed  CAS  Google Scholar 

  37. Nakamura T, Matsuda T, Suzuki Y, et al.: Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. ASAIO J 2003, 49:430–434.

    PubMed  CAS  Google Scholar 

  38. Kojima S, Shida M, Yokoyama H: Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Ther Apher Dial 2003, 7:431–434.

    Article  PubMed  CAS  Google Scholar 

  39. Kobayashi S, Moriya H, Maesato K, et al.: LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. J Clin Apher 2005, 20:239–243.

    Article  PubMed  Google Scholar 

  40. Moriarty PM, Gibson CA: Effects of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2. Am J Cardiol 2005, 95:1246–1247.

    Article  PubMed  CAS  Google Scholar 

  41. Tamai O, Matsuoka H, Itabe H, et al.: Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 1997, 95:76–82.

    PubMed  CAS  Google Scholar 

  42. Stadler RW, Ibrahim SF, Lees RS: Peripheral vasoactivity in familial hypercholesterolemic subjects treated with heparin-induced extracorporeal LDL precipitation (HELP). Atherosclerosis 1997, 128:241–249.

    Article  PubMed  CAS  Google Scholar 

  43. Napoli C, Ambrosio G, Scarpato N, et al.: Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J 1997, 133:585–595.

    Article  PubMed  CAS  Google Scholar 

  44. Mellwig KP, Baller D, Gleichmann U, et al.: Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 1998, 139:173–178.

    Article  PubMed  CAS  Google Scholar 

  45. Cashin-Hemphill L, Noone M, Abbott JF, et al.: Low-density lipoprotein apheresis therapy during pregnancy. Am J Cardiol 2000, 86:1160, A10.

    Article  PubMed  CAS  Google Scholar 

  46. Kroon AA, Swinkels DW, van Dongen PW, et al.: Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis. Metabolism 1994, 43:1164–1170.

    Article  PubMed  CAS  Google Scholar 

  47. US Food and Drug Administration, US Department of Health and Human Services: Premarket approval of Kaneka America Corporation Liposorber LA-15 System—action [Public Health Service memorandum]. Available at http://www.fda.gov/cdrh/pdf/p910018.pdf. Accessed May 2009.

  48. US Food and Drug Administration, US Department of Health and Human Services: Re 940016. H.E.L.P. (Heparin-induced Extracorporeal Lipoprotein Precipitation) [Public Health Service letter]. Available at http://www.fda.gov/cdrh/pdf/p940016.pdf. Accessed May 2009.

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Center for Heart Disease Prevention, Emory University School of Medicine, 1525 Clifton Road, Suite 214, Atlanta, GA, 30322, USA

    Laurence S. Sperling

Authors
  1. Puja K. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jefferson Baer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Nell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laurence S. Sperling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurence S. Sperling.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mehta, P.K., Baer, J., Nell, C. et al. Low-density lipoprotein apheresis as a treatment option for hyperlipidemia. Curr Treat Options Cardio Med 11, 279–288 (2009). https://doi.org/10.1007/s11936-009-0029-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-009-0029-1

Keywords

Search

Navigation